We're fighting antibiotic-resistant #superbugs with our innovative synthetic anti-infectives! 💊 🔬✨ #Innovation #AntibioticResistance #UTI #DFI.

Recce isn’t following the traditional path, and for a good reason. In this Q&A, our CEO James Graham shares how Recce’s synthetic approach is designed to stay ahead of resistance and deliver faster, more effective treatments for patients worldwide. #ReccePharma #AMR

For the past few years, Recce has shared new data on RECCE® 327 at the Military Health System Research Symposium (MHSRS). We’re proud to continue this journey and will return to MHSRS 2025 to present our latest findings.

Burn wounds are among the most infection‑prone injuries, and drug‑resistant bacteria make them even harder to treat. Burn units worldwide face complex challenges that delay healing and raise mortality. Awareness is the first step toward driving innovation in burn care.

Big breakthroughs start with precision. Every test, every detail in the lab matters. Michele Dilizia, Recce’s Chief Scientific Officer, brings years of expertise to every step of our work on a new class of anti‑infectives. #ReccePharma #AMR #Superbugs #R327 #Biotech

Diabetes affects over 38 million people in the U.S., and foot ulcers remain one of its most serious complications. As drug‑resistant infections rise, understanding the scale of this challenge is key to shaping future treatment options.

From investing in his grandfather’s research to now leading Recce towards commercialisation. James Graham’s journey as a CEO reflects Recce’s core values of innovation and determination. In this Q&A, James shares what inspires him, the challenges we’ve faced, and why this work

Biotech is full of acronyms. Here’s what they mean, and why they matter. Breaking them down makes it easier to follow Recce’s progress.

Some infections don’t wait days to spread; they can progress in hours. That’s why early recognition and effective treatments are critical, especially as drug resistance rises. Raising awareness is part of fighting back.

Superbugs aren’t just a hospital problem. They spread through food, water, and even silently in healthy people. #AMR #Superbugs #AntibioticResistance #GlobalHealth #InfectiousDiseases #ReccePharma

Drug‑resistant infections aren’t just a health threat; they come with a massive hidden cost. Swipe to see how resistance is impacting the healthcare system.

From lab to life, here’s how clinical trials work. Every new treatment must go through a series of rigorous stages to prove its safety and effectiveness. Here’s a breakdown of how it works and where Recce’s programs currently stand.

Most antibiotics are discovered in nature, but nature has limits. Recce’s anti-infectives are fully synthetic, fast-acting, broad-spectrum, and designed to beat resistance. Innovation starts at the molecular level. #SyntheticAntibiotics #ReccePharma #AMR #Superbugs

Antibiotics make routine procedures safer, from C-sections to joint replacements. But antibiotic resistance is rising. Infections are lasting longer, costing more, and getting harder to treat.

Serious infections aren’t just clinical challenges. They affect lives, routines, and recovery. At Recce, we’ve designed anti-infectives that act fast and overcome resistance, because every day of delayed healing matters. #WoundCare #DFI #Superbugs #AMR #ReccePharma

Some of the most dangerous infections start where we least expect them, on the surface. R327G is being developed to treat serious topical infections, from diabetic foot infections to burns. With strong clinical results, it's designed to act fast and fight resistance where it

Not all infections start deep inside the body. Some begin on the surface and can become dangerous if they spread or overwhelm the body’s defenses. That’s why treating topical infections early and effectively is so important. #TopicalInfections #WoundCare #AntiInfectives

What is a diabetic foot infection?.It’s one of the most common and serious complications of diabetes. When foot ulcers become infected, they can take much longer to heal and may lead to major complications. Raising awareness is the first step.

Some wounds do more than hurt, especially when resistant bacteria are involved. That’s why Recce developed R327G, a topical anti-infective targeting:. 🔹 Diabetic foot infections.🔹 Burn wounds.🔹 Skin and soft tissue infections.

When infections move quickly, every minute matters. R327 is designed to act fast, disrupting bacterial energy production within minutes of contact. That means faster control of serious infections and a smarter response to resistance.

Did you know?.Most of the antibiotics we use today were discovered before the 1980s. Bacteria have changed since then. Our medicines? Not so much. With resistance on the rise, we’re relying on old tools for a growing problem. We need innovation, urgently. #R327 #AMR #Superbugs